Retatrutide vs Cagrilintide: What the Research Actually Shows
Two experimental peptides, two different receptor strategies, and a growing body of clinical data. Here's what the published evidence actually says about each.
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors, while cagrilintide is a long-acting amylin analogue that works through amylin and calcitonin receptors. Both are in active clinical development for obesity and metabolic conditions, but neither is FDA approved as a standalone research compound. Phase 2 human trial data exists for both, with retatrutide showing up to 24.2% mean body weight reduction over 48 weeks in one Eli Lilly-sponsored trial, and cagrilintide showing dose-dependent weight loss in a Novo Nordisk-sponsored Phase 2 trial.
How Each Compound Works at the Receptor Level
Retatrutide, developed by Eli Lilly, is a single peptide molecule that simultaneously activates three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple-agonist design separates it from earlier GLP-1 single agonists and dual GIP/GLP-1 agonists like tirzepatide. The glucagon receptor component is particularly notable because glucagon stimulates energy expenditure and fat oxidation in the liver, adding a mechanism that pure GLP-1 agonists lack.
Cagrilintide, developed by Novo Nordisk, takes a completely different approach. It is a long-acting analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin acts on amylin receptors and calcitonin receptors in the brain, particularly in the area postrema and hypothalamus, to slow gastric emptying, suppress glucagon secretion, and reduce food intake. Cagrilintide is engineered with fatty acid side chains that extend its half-life, allowing once-weekly subcutaneous administration in trials. The amylin pathway is biologically distinct from the incretin axis that GLP-1 agonists target, which is why Novo Nordisk is also studying cagrilintide in combination with semaglutide under the name CagriSema.
What Do the Human Trials Show for Retatrutide?
The most cited retatrutide data comes from a Phase 2 randomized controlled trial published in The New England Journal of Medicine in 2023. That trial enrolled 338 adults with obesity or overweight plus at least one weight-related condition. Participants were assigned to placebo or one of several retatrutide dose levels over 48 weeks. The highest-dose group achieved a mean body weight reduction of 24.2%, a figure that drew significant attention because it exceeded what had been reported for semaglutide and approached results seen with bariatric surgery in some populations.
The same trial reported dose-dependent reductions in waist circumference, fasting insulin, and triglycerides. Adverse events were consistent with the GLP-1 class: nausea, vomiting, diarrhea, and constipation were the most common, predominantly during the escalation period. Serious adverse events occurred in roughly 8% of participants across active arms. The trial was not powered to assess cardiovascular outcomes, and no long-term safety data from multi-year studies exists yet. Retatrutide is currently in Phase 3 trials for obesity and type 2 diabetes, but it has not received FDA approval in any form.
What Do the Human Trials Show for Cagrilintide?
Cagrilintide's standalone Phase 2 data comes from a trial published in The Lancet in 2021, which enrolled 706 adults with overweight or obesity. Over 26 weeks, participants receiving the highest dose tested (4.5 mg weekly) lost a mean of 10.8% of body weight compared to 3.0% in the placebo group. The trial demonstrated clear dose-response relationships across five active dose levels, and the compound was generally well tolerated, with nausea and injection-site reactions as the most common adverse events.
The more strategically significant research involves CagriSema, the fixed-ratio combination of cagrilintide and semaglutide. A Phase 2 trial published in The Lancet in 2023 showed that CagriSema produced approximately 15.6% weight loss over 32 weeks in adults with overweight or obesity, which exceeded what either component achieved alone in comparable trials. This additive effect supports the hypothesis that targeting amylin receptors alongside GLP-1 receptors engages complementary satiety pathways. Novo Nordisk has advanced CagriSema into Phase 3 trials under the name REDEFINE, but cagrilintide as a standalone compound is not FDA approved, and the combination product has no approved status either.
Regulatory Status and the Research-Chemical Distinction
Neither retatrutide nor cagrilintide has received FDA approval in any form as of mid-2025. Retatrutide is an investigational compound owned by Eli Lilly, currently in Phase 3 trials. Cagrilintide is an investigational compound owned by Novo Nordisk, studied both alone and as part of CagriSema in Phase 3. This is a meaningful distinction from other peptides in the incretin class: semaglutide is FDA approved as Ozempic and Wegovy for specific indications, and tirzepatide is FDA approved as Mounjaro and Zepbound. Those approvals apply to the specific branded pharmaceutical products and do not extend to research-chemical versions sold by third-party vendors.
Peptides labeled as retatrutide or cagrilintide sold by research chemical vendors exist entirely outside the pharmaceutical supply chain. They carry no FDA approval and no verified manufacturing standards tied to any regulatory body. Certificates of analysis from third-party labs can confirm purity and identity of a vendor's batch, but a COA does not confer approval status or validate safety for human use. Anyone reviewing vendor claims for these compounds should apply the same skepticism used for any unapproved research chemical.
How Do the Two Compounds Compare Directly?
The most obvious difference is mechanism. Retatrutide works through three incretin and metabolic receptors simultaneously, while cagrilintide works through the amylin and calcitonin receptor system. These are non-overlapping pathways, which is precisely why researchers are studying amylin-based compounds alongside GLP-1 agonists rather than as substitutes for them. The two compounds are not interchangeable in research design or in the questions they are meant to answer.
On the evidence side, retatrutide's 48-week Phase 2 data currently shows a larger magnitude of weight reduction than cagrilintide's standalone 26-week data, though direct head-to-head trials do not exist and the study durations differ. Cagrilintide's most compelling data may actually be its combination data with semaglutide, suggesting its value in research is partly as a complementary agent rather than a standalone one. Both compounds have meaningful human RCT data, which puts them ahead of many peptides circulating in the research chemical market that rely entirely on animal or in-vitro studies. That said, neither has completed Phase 3, and long-term cardiovascular and safety outcomes remain open questions for both.
Vetted vendors for research use
Our index screens vendor documentation against the checks in this review. We never accept payment for rank placement.
Frequently asked questions
Are retatrutide and cagrilintide being studied for the same conditions?
There is overlap but also divergence. Both have been studied in adults with overweight or obesity, and both Eli Lilly and Novo Nordisk have type 2 diabetes in their development programs. Cagrilintide is also being studied specifically as a component of CagriSema, the combination with semaglutide, which is Novo Nordisk's primary Phase 3 focus for the compound. Retatrutide's Phase 3 program includes separate obesity and type 2 diabetes arms as a standalone agent.
Does the glucagon receptor component in retatrutide raise safety concerns?
It is a question researchers are actively examining. Glucagon receptor activation raises theoretical concerns about hepatic glucose output and potential effects on heart rate. The 2023 Phase 2 NEJM trial reported that heart rate increases were observed in retatrutide participants, a finding consistent with glucagon receptor activity. The trial was not designed to assess long-term cardiovascular outcomes, so the clinical significance of that finding remains under study in Phase 3.
What is the difference between cagrilintide and pramlintide?
Both are amylin analogues, but they differ substantially in pharmacokinetics. Pramlintide, sold as Symlin, is FDA approved as an adjunct to insulin therapy and requires multiple daily injections due to its short half-life. Cagrilintide is engineered with fatty acid modifications that allow once-weekly administration, which is the design feature that makes it practical for the obesity trials Novo Nordisk is running. The two compounds are not interchangeable, and cagrilintide does not carry pramlintide's FDA approval.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
- Jastreboff et al., 2023, New England Journal of Medicine Phase 2 RCT of retatrutide in obesity
- Enebo et al., 2021, The Lancet Phase 2 RCT of cagrilintide in obesity
- Lau et al., 2023, The Lancet Phase 2 RCT of CagriSema combination
- ClinicalTrials.gov NCT05394519 Retatrutide Phase 3 obesity trial registration
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
